103 related articles for article (PubMed ID: 18649357)
1. Clusterin is epigenetically regulated in prostate cancer.
Rauhala HE; Porkka KP; Saramäki OR; Tammela TL; Visakorpi T
Int J Cancer; 2008 Oct; 123(7):1601-9. PubMed ID: 18649357
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer.
Pang ST; Weng WH; Flores-Morales A; Johansson B; Pourian MR; Nilsson P; Pousette A; Larsson C; Norstedt G
Prostate; 2006 Feb; 66(2):157-72. PubMed ID: 16173030
[TBL] [Abstract][Full Text] [Related]
4. Distinct promoters, subjected to epigenetic regulation, drive the expression of two clusterin mRNAs in prostate cancer cells.
Bonacini M; Coletta M; Ramazzina I; Naponelli V; Modernelli A; Davalli P; Bettuzzi S; Rizzi F
Biochim Biophys Acta; 2015 Jan; 1849(1):44-54. PubMed ID: 25464035
[TBL] [Abstract][Full Text] [Related]
5. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G
Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763
[TBL] [Abstract][Full Text] [Related]
6. Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers.
Yamashita S; Takahashi S; McDonell N; Watanabe N; Niwa T; Hosoya K; Tsujino Y; Shirai T; Ushijima T
Cancer Res; 2008 Apr; 68(7):2112-21. PubMed ID: 18381416
[TBL] [Abstract][Full Text] [Related]
7. Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer.
Bermudo R; Abia D; Ferrer B; Nayach I; Benguria A; Zaballos A; del Rey J; Miró R; Campo E; Martínez-A C; Ortiz AR; Fernández PL; Thomson TM
BMC Cancer; 2008 Oct; 8():315. PubMed ID: 18973659
[TBL] [Abstract][Full Text] [Related]
8. RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer.
Porkka KP; Tammela TL; Vessella RL; Visakorpi T
Genes Chromosomes Cancer; 2004 Jan; 39(1):1-10. PubMed ID: 14603436
[TBL] [Abstract][Full Text] [Related]
9. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer.
Rauhala HE; Jalava SE; Isotalo J; Bracken H; Lehmusvaara S; Tammela TL; Oja H; Visakorpi T
Int J Cancer; 2010 Sep; 127(6):1363-72. PubMed ID: 20073067
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression.
Lodygin D; Diebold J; Hermeking H
Oncogene; 2004 Dec; 23(56):9034-41. PubMed ID: 15489902
[TBL] [Abstract][Full Text] [Related]
11. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer.
Schulz WA; Alexa A; Jung V; Hader C; Hoffmann MJ; Yamanaka M; Fritzsche S; Wlazlinski A; Müller M; Lengauer T; Engers R; Florl AR; Wullich B; Rahnenführer J
Mol Cancer; 2007 Feb; 6():14. PubMed ID: 17280610
[TBL] [Abstract][Full Text] [Related]
12. Clusterin (CLU) and prostate cancer.
Rizzi F; Bettuzzi S
Adv Cancer Res; 2009; 105():1-19. PubMed ID: 19879420
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation pathway alterations in an autochthonous murine model of prostate cancer.
Morey SR; Smiraglia DJ; James SR; Yu J; Moser MT; Foster BA; Karpf AR
Cancer Res; 2006 Dec; 66(24):11659-67. PubMed ID: 17178860
[TBL] [Abstract][Full Text] [Related]
14. Simultaneously detection of genomic and expression alterations in prostate cancer using cDNA microarray.
Jiang M; Li M; Fu X; Huang Y; Qian H; Sun R; Mao Y; Xie Y; Li Y
Prostate; 2008 Oct; 68(14):1496-509. PubMed ID: 18366025
[TBL] [Abstract][Full Text] [Related]
15. Global reactivation of epigenetically silenced genes in prostate cancer.
Ibragimova I; Ibáñez de Cáceres I; Hoffman AM; Potapova A; Dulaimi E; Al-Saleem T; Hudes GR; Ochs MF; Cairns P
Cancer Prev Res (Phila); 2010 Sep; 3(9):1084-92. PubMed ID: 20699414
[TBL] [Abstract][Full Text] [Related]
16. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.
Caporali A; Davalli P; Astancolle S; D'Arca D; Brausi M; Bettuzzi S; Corti A
Carcinogenesis; 2004 Nov; 25(11):2217-24. PubMed ID: 15358631
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
Ibanez de Caceres I; Dulaimi E; Hoffman AM; Al-Saleem T; Uzzo RG; Cairns P
Cancer Res; 2006 May; 66(10):5021-8. PubMed ID: 16707423
[TBL] [Abstract][Full Text] [Related]
18. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
Sørensen KD; Borre M; Ørntoft TF; Dyrskjøt L; Tørring N
Int J Cancer; 2008 Feb; 122(3):509-19. PubMed ID: 17943724
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
20. Functional epigenomics identifies genes frequently silenced in prostate cancer.
Lodygin D; Epanchintsev A; Menssen A; Diebold J; Hermeking H
Cancer Res; 2005 May; 65(10):4218-27. PubMed ID: 15899813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
